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Abstract
Purpose
The main objective of this study is to compare the protein expression of human keratocytes
treated with Plasma rich in growth factors (PRGF) or autologous serum (AS) and previously
induced to myofibroblast by TGF-β1 treatment.
Methods
Blood from healthy donor was collected and processed to obtain AS and PRGF eye drops.
Blood derivates were aliquoted and stored at -80˚C until use. Keratocyte cells were pre-
treated for 60 minutes with 2.5 ng/ml TGF-β1. After that, cells were treated with PRGF, AS
or with TGF-β1 (control). To characterize the proteins deregulated after PRGF and AS treat-
ment, a proteomic approach that combines 1D-SDS–PAGE approach followed by LC–MS/
MS was carried out.
Results
Results show a catalogue of key proteins in close contact with a myofibroblastic differenti-
ated phenotype in AS treated-cells, whereas PRGF-treated cells show attenuation on this
phenotype. The number of proteins downregulated after PRGF treatment or upregulated in
AS-treated cells suggest a close relationship between AS-treated cells and cytoskeletal
functions. On the other hand, proteins upregulated after PRGF-treatment or downregulated
in AS-treated cells reveal a greater association with processes such as protein synthesis,
proliferation and cellular motility.
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Conclusion
This proteomic analysis helps to understand the molecular events underlying AS and
PRGF-driven tissue regeneration processes, providing new evidence that comes along with
the modulation of TGF-β1 activity and the reversion of the myofibroblastic phenotype by
PRGF.
Introduction
The increase of population age is associated with an augmentation of the ophthalmological
problems concerning the ocular surface and the cornea. These complications are mainly due
to age-specific hormonal changes, autoimmune diseases (as rheumatoid arthritis or systemic
lupus erythematosus) or are also caused by local infections [1–3].
The treatment of ocular surface disorders (OSDs) could be addressed in a step by step
approach implying topic and local medical therapy as lubricating artificial tears, anti-inflam-
matory substances (corticoids or cyclosporine or secretagogues) and, blood derived eye drops
such as autologous serum and platelet rich plasmas (PRP), including Plasma Rich in Growth
Factors (PRGF) eye drops [4–8].
New interesting regenerative therapies for the treatment of different pathologies are used
today in the ophthalmology field including amniotic membrane transplantation (AMT) and
the use of recombinant growth factors [9]. However, the uncertain results obtained after the
application of AMT, the elevated manufacturing costs and the scarce clinical results, make it
necessary to explore other therapeutic alternatives for corneal regeneration [10–12]. In this
sense, PRGF-Endoret arises as a very promising therapeutic option with proven efficacy both
in vitro and in vivo [13].
Corneal surface regenerative process depends on a myriad of interacting growth factors
(epidermal growth factor (EGF), transforming growth factor beta (TGF-β1), keratinocyte
growth factor (KGF), hepatocyte growth factor (HGF), platelet derived growth factor (PDGF)
and fibroblast growth factor (FGF) among others) that coordinate biological events leading
to an appropriate tissue regeneration [14]. Autologous serum (AS) has been classically
employed for ocular surface disorders (OSD) due to its content in growth factors. The lack of a
standardized manufacturing protocol, the high content in pro-inflammatory molecules
(metalloproteinases and hydrolases) together with microbial contamination elevated risk, pro-
vide controversial AS clinical results [15, 16]. In order to avoid these limitations, a protocolized
and standardized technology has been developed, PRGF eye drops, an autologous hemoderi-
vate obtained by means of a closed system that includes platelet activation, avoiding leukocytes
and pro-inflammatory molecules and with higher growth factor content than autologous
serum. Other important features of PRGF eye drops in tissue regeneration relies on its bacteri-
ostatic/bactericidal activity, its anti-fibrotic and anti-inflammatory potential, and its proven
biological stability for at least 6 months [17]. In vitro studies have highlighted the beneficial
effects of PRGF eye drops on human primary ocular surface cells accelerating corneal wound
closure and increasing corneal epithelial cell proliferation and migration [18, 19]. An in vivo
study demonstrated that PRGF eye drops reduced the re-epithelization time in comparison to
a platelet rich plasma without platelet activation and compared to autologous serum [20]. In
the case of a stromal injury, some fibroblasts develop actin contractile filaments and differenti-
ate into myofibroblasts. However, the persistence of myofibroblastic cells after wound healing
lead to the development of a corneal fibrotic scar and haze. PRGF eye drops exerts a protective
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effect against fibrotic scars formation by avoiding the transformation of TGF-β1-treated stro-
mal fibroblasts to myofibroblasts [21], suggesting the beneficial effects of PRGF to promote
corneal regeneration and minimizing scar formation [20, 22, 23].
PRGF eye drops low cost and easy production and its demonstrated ophthalmic clinical
efficacy converts this autologous technology in a new promising human therapy over other
hemoderivate products like autologous serum [24–28]. In this way, proteomic characterization
of PRGF-treated cells could help to understand regenerative therapy processes and mecha-
nisms and contribute in the optimization of eye drops application and dosage.
In the present study, the differential protein expression of TGF-β1-induced myofibroblasts
treated with either Plasma rich in growth factors (PRGF) or autologous serum (AS) was deter-
mined. The latter could shed light on corneal haze reduction after PRGF application.
Materials and methods
In order to use human-based PRGF, this study was approved by the Ethics Committee of the
Eduardo Anitua Foundation for biomedical research on March 17, 2015. The ethics approval
was obtained prior to the start of the experimental study. With the aim of characterizing the
proteomic profile of human keratocytes after treatment with PRGF eye drops and autologous
serum (AS), they were stimulated with TGF-β1 for differentiating them to myofibroblasts and
then were treated with PRGF or AS to reverse the myofibroblastic phenotype. Corneal stromal
keratocytes cells (termed HK) were pretreated with TGF-β1 + 0.1% FBS and afterwards were
divided in 3 treatment groups: PRGF-Endoret + TGF-β1 or AS + TGF-β1, using TGF-β1
+ 0.1% FBS as a control. Then, cell sediments were obtained and samples were subjected to the
FAST protocol for protein digestion, being the obtained proteins identified by LC-MS (Liquid
Chromatography–Mass Spectrometry) [29] and further quantified in order to dig into protein
expression differences triggered by PRGF and AS treatments. Protein functional analyses were
carried out for a deeper understanding of the molecular events underlying such changes.
PRGF and autologous serum (AS) preparations
Blood from one healthy young male donor was harvested after informed consent into 9-mL
tubes with 3.8% (wt/v) sodium citrate or in serum collection tubes (Z Serum Clot activator,
Vacuette, GmbH, Kremsmu¨nster, Austria). The study was performed following the principles
of the Declaration of Helsinki. Blood sample for PRGF was centrifuged at 580 g for 8 min at
room temperature in an Endoret System centrifuge (BTI Biotechnology Institute, S.L.,
Miñano, A´lava, Spain); the whole plasma column over the buffy coat was collected using
Endoret ophthalmology kit (BTI Biotechnology Institute, S.L., Miñano, A´lava, Spain) avoiding
leukocytes collection. The obtained PRGF supernatants were filtered, aliquoted and stored at
-80˚C until use. Blood sample for autologous serum preparation was allowed to clot at room
temperature for 20 minutes and subsequently centrifuged for 10 min at 2000 g; after that,
serum was collected and filtered by 0.22 μm PVDF filters. Then, total serum was diluted to
20% with sterile serum saline, aliquoted and stored at -80˚C until use (termed AS).
Cells
Cells involved in assays were corneal stromal keratocytes (termed HK) (ScienCell Research
Laboratories, San Diego, CA) that were cultured according to manufacturer’s instructions.
Briefly, cells were maintained in culture until confluence in Fibroblast medium supplemented
with Fibroblast Growth Supplement (FGS), 2% fetal bovine serum (FBS) and antibiotics (peni-
cillin/streptomycin) (ScienCell Research Laboratories, San Diego, CA, USA) and then were
detached with animal origin-free trypsin-like enzyme (TrypLE Select, Gibco-Invitrogen,
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Grand Island, NY, USA). Cell viability was assessed by trypan blue dye exclusion. Passage 4
cells were used in all experiments.
Myofibroblast differentiation: Reversion assay
In order to test the capacity of reversion of PRGF versus AS, HK cells were pretreated for 60
minutes with 2.5 ng/ml TGF-β1 + 0.1% FBS (TGF-β1, Chemicon-Millipore, Billerica, MA,
USA); afterwards, medium was removed and wells were washed with phosphate buffered
saline (PBS) in order to place the treatments for 30 minutes: 20% PRGF + 2.5 ng/ml TGF-β1
(termed PRGF) or 20% AS + 2.5 ng/ml TGF-β1 (termed AS), 2.5 ng/ml TGF-β1 + 0.1% FBS
(termed control) was used as a control. Then, culture media were discarded and wells were
rinsed with PBS and cells were collected with TrypLE. After centrifugation at 1500 rpm for 5
min, the cell pellets were incubated for 1h at room temperature with cell lysis buffer consisting
on Tris 30 mM, thiourea 2 M, urea 7 M, CHAPS 4% (all from Sigma–Aldrich, St Louis, MO,
USA) and distilled water in order to obtain the proteins. Finally, the supernatants were col-
lected after centrifugation at 13000 rpm for 5 min, aliquoted and stored at -20˚C until use.
Samples were assayed in quadruplicate for each treatment.
Fig 1 summarizes the general schema of the followed steps. Stromal keratocytes were treated
with TGF-β1 in order to transform them to myofibroblasts and then reversion assay was per-
formed; PRGF and AS treatments were analyzed to find differences in protein expression with
mass spectrometry (LC-MS analysis).
Protein digestion and LC-MS analysis (Liquid chromatography–mass
spectrometry)
Samples were digested following the FASP protocol [29] with minor variations. Peptides were
cleaned up with C18 Zip Tip stage tips (Chemicon-Millipore, Billerica, MA, USA) and loaded
Fig 1. Human keratocytes were stimulated with TGF-β1 in order to induce a myofibroblastic phenotype and then were treated with TGF-β1 alone or in
combination with PRGF or AS eye drops. After cell collection and protein extraction, tryptic digestion and Liquid chromatography–mass spectrometry
(LC-MS) analysis were performed.
https://doi.org/10.1371/journal.pone.0205073.g001
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onto a nanoACQUITY UPLC System (Waters Corporation, Milford, MA, USA) connected to
an LTQ Orbitrap XL mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA). An
aliquot of each sample was loaded onto a Symmetry 300 C18 UPLC Trap column (180 μm x 20
mm, 5 μm (Waters Corporation, Milford, MA, USA)). The precolumn was connected to a
BEH130 C18 column, 75 μm x 200 mm, 1.7 μm (Waters Corporation, Milford, MA, USA),
and equilibrated in 3% acetonitrile and 0.1% aqueous formic acid. Peptides were eluted
directly into the nanoelectrospray capillary (Proxeon Biosystems, Thermo Fisher Scientific,
Waltham, MA, USA) at 300 nl/min, using a 30 min linear gradient of 3–50% acetonitrile for
DIGE spots, or a 60 min linear gradient of 3–50% acetonitrile for LF samples. The mass spec-
trometer automatically switched between MS and MS/MS acquisition in DDA mode. Full MS
scan survey spectra (m/z 400–2000) were acquired in the orbitrap with mass resolution of
30000 at m/z 400. After each survey scan, the six most intense ions above 1000 counts were
sequentially subjected to collision-induced dissociation (CID) in the linear ion trap. Precursors
with charge states of 2 and 3 were specifically selected for CID. Peptides were excluded from
further analysis during 60 s using the dynamic exclusion feature.
Differential analysis
Progenesis LC-MS (version 4.0.4265.42984, Nonlinear Dynamics) was used for the label-free
differential protein expression analysis. After importing the Raw files from the MS acquisition
of the samples to the program, one of the runs was used as the reference to which the precursor
masses in all other samples were aligned to. Only features comprising charges of 2+ and 3
+ were selected. The raw abundances of each feature were automatically normalized and loga-
rithmized against the reference run. Samples were grouped in accordance to the comparison
being performed, and an ANOVA analysis was performed. Features with an ANOVA p-
value� 0.05 and a ratio>1.5 in either direction was only considered. A peak list containing
the information of these significantly different features was generated and exported to the
Mascot search engine (Matrix Science Ltd.).
The generated mgf file was searched against Uniprot/Swissprot human database, consider-
ing Cysteine Carbamidomethylation as fixed modification and oxidation of methionine as var-
iable modification. 10 ppm of peptide mass tolerance and 0.5 Da fragment mass tolerance
were used, and 2 missed cleavages were allowed. Spectra were searched against Uniprot/Swis-
sprot database restricted to human entries, and only hits with a FDR<1% were kept. The list of
identified peptides was imported back to Progenesis LC-MS, and the previously quantified fea-
tures were matched to the corresponding peptides. Non-conflicting peptides (peptides occur-
ring in only one protein) were specifically chosen for quantitative purposes, and only proteins
with at least two quantified non-conflicting peptides were selected. The significance of expres-
sion changes was again tested at protein level, and proteins not satisfying the ANOVA p-
value� 0.05 and Ratio>1.5 in either direction criteria were filtered out.
Functional analysis
GO enrichment analysis was carried out using the DAVID online tool (http://david.abcc.
ncifcrf.gov/summary.jsp).[30, 31] DAVID is a GO Term annotation and enrichment analysis
tool used to highlight the most relevant GO terms associated with a given gene list. A Fisher
Exact test is used in order to determine whether the proportion of genes considered into cer-
tain GO term or categories differ significantly between the dataset and the background. A
FDR-corrected version of the Fisher’s test p-value can be obtained and used for more conser-
vative result selection. Biological Process (BP), Molecular Function (MF) and Cellular
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Component (CC) categories were assessed, and only GO Terms enriched with a p value < 0.05
were considered for comparison and discussion.
Ingenuity Pathway Analysis (IPA, QIAGEN Redwood City, www.qiagen.com/ingenuity)
was used for the functional analysis of the proteins identified. The calculated p-values deter-
mine the probability that the association between proteins in the dataset and a given canonical
pathway, functional network or upstream regulator is explained by chance alone, based on a
Fisher’s exact test (p-value < 0.05 considered as significant). Activation z-score represents the
bias in gene regulation that predicts whether the upstream regulator exists in an activated (pos-
itive values) or inactivated (negative values) state, based on the knowledge of the relation
between the effectors and their target molecules. All relevant data are within the paper and its
supporting information files.
Results
Differential analysis
Protein samples coming from the three conditions (PRGF, AS and control) were analyzed for
differential expression using Progenesis QI software (Fig 2). Three comparisons were per-
formed, namely Control vs. PRGF, Control vs. AS and PRGF vs. AS. Proteins with at least two
non-conflictive peptides and a p value<0.05 and a ratio>1.5 in either direction and in any of
the comparisons were selected for further analysis (Tables A through D of S1 File). The num-
ber of deregulated proteins in each comparison was 157, 228 and 202, respectively (Fig 2A).
The Venn diagram in Fig 2B summarizes the intersection of the differential proteins from the
three analyzed comparisons. After careful evaluation of the PRGF vs. AS comparison, we real-
ized that from the 202 deregulated proteins, a total of 71 were shared by all comparisons, that
is, C vs PRGF, C vs AS and PRGF vs AS. Furthermore, 72 proteins were shared by just 2 com-
parisons (C vs AS and PRGF vs AS) while 19 proteins were shared by the comparisons C vs
PRGF and PRGF vs AS (Fig 2B).
It might be relevant to describe some of the deregulated proteins that are observed in the
PRGF vs. AS comparison. For example, among the 71 shared proteins by all combinations, it is
remarkable to distinguish some proteins up-regulated after AS-treatment: vinculin (VINC),
integrin β1 (ITGB1) and actinin 1 (ACTN1), and other proteins as profilin 1 (PFN1) downre-
gulated after AS-treament. Some other deregulated proteins that are shared by two of the com-
parisons include vimentin (VIM) (shared by C vs PRGF and PRGF vs AS), and cortactin
(CTTN), actin-related protein-3 (ACTR3) and myosins like myosin-10 (MYH10) and myosin-
12 (MYL12A) (shared by C vs AS and PRGF vs AS), all of them up-regulated after AS treat-
ment. In addition, some proteins are only specific to the comparison of PRGF vs AS, as actin-
related protein-2 (ACTR2) that is up-regulated in AS-treatment or septin-9 (SEPT9) that is
up-regulated in PRGF-treatment (Tables A through D of S1 File).
Functional analysis
A Gene Ontology (GO) analysis was carried out for the deregulated proteins, with the aim of
characterizing roughly the functional processes these proteins are involved in. Processes
enriched with a Fisher’s exact test p value<0.05 were selected for each of the protein lists and
further compared (Tables E through I of S2 File). Interestingly, some GO Terms related to
cytoskeleton function, such as “cytoskeleton” (p value 4.48E-06) and “regulation of cytoskele-
ton organization” (p value 3.98E-05) were exclusively enriched in the C vs AS dataset, being
absent from the PRGF treatment. In addition, other cytoskeleton-related terms, such as “cyto-
skeletal protein binding” or “actin cytoskeleton” were related to both PRGF and AS
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treatments, but the significance of the correlation of those processes was much higher with the
AS protein dataset (Tables E through I of S2 File).
IPA was accomplished for further characterizing the functional processes in which the
deregulated proteins are involved (Tables J through L of S3 File). Fig 3 summarizes the canoni-
cal pathways that are most differentially associated to each of the treatments, that is, the path-
ways with the highest p-value difference between PRGF and AS treatments. This analysis
revealed that these canonical pathways are distributed mainly in three relevant biological func-
tions: A) Actin cytoskeleton signaling, B) Integrins and their signal transduction, and C)
Fig 2. Deregulated proteins upon PRGF eye drops and AS treatment. A) Total number of differential proteins in the
different comparisons performed. B) Venn diagram depicting the overlap degree between the differential proteins in
each comparison.
https://doi.org/10.1371/journal.pone.0205073.g002
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Protein synthesis, cell proliferation and motility. Eight of 17 canonical pathways are related to
actin cytoskeleton signaling, including Actin Cytoskeleton Signaling, Regulation of Actin-
based Motility by Rho, RhoA Signaling, Signaling by Rho Family GTPases, RhoGDI Signaling,
Cdc42 Signaling, Actin Nucleation by ARP-WASP Complex, and PAK Signaling, (Fig 3A).
Again, the significance of the association between the proteins deregulated upon AS treatment
and these cytoskeleton-related terms is higher than with PRGF, suggesting a tight correlation
between AS and cytoskeletal functions. Six of the canonical pathways (Integrin Signaling, Epi-
thelial Adherens Junction Signaling, Remodeling of Epithelial Adherens Junctions, ILK Signal-
ing, FAK Signaling and Paxillin Signaling) are related to integrins and their signal
transduction (Fig 3B). Integrin signaling seems to be more strongly correlated to AS treatment,
although ILK signaling and FAK signaling are more significant among the PRGF-deregulated
proteins. Finally, the rest 3 of 17 pathways (EIF2 Signaling, Regulation of eIF4 and p70S6K
Fig 3. Canonical pathways analysis of the differential proteins. The most significantly enriched canonical pathways (–log p
values in the y axis) are displayed. The results are clustered in functionally-related groups of processes: actin cytoskeleton
signalling (A), integrins and their signal transduction (B), and protein synthesis, cell proliferation and motility (C).
https://doi.org/10.1371/journal.pone.0205073.g003
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Signaling and mTOR Signaling), are associated with protein synthesis, cell proliferation and
motility (Fig 3C), and are more significantly related to PRGF-mediated response.
Furthermore, the IPA upstream regulators analysis revealed a differential activation of the
TGF-β1 pathway depending on the treatment. The expression pattern of the deregulated pro-
teins upon PRGF or AS treatment revealed a strong correlation with TGF-β1 signaling (-log p
value 10.69 and 19.25, respectively), suggesting an important signaling mediated by this cyto-
kine for the phenotype of these cells. But in addition to this observation, the direct comparison
between PRGF and AS-treated cells revealed that the degree of activation was different, sug-
gesting that TGF-β1 is inhibited (or less activated) in PRGF-treated cells (Fig 4A, z-score
-1.51). The activation state of additional TGF-β1-related upstream regulators, such as SMAD-
3 (Fig 4B, z-score -0.55) and SMAD-4 (Fig 4C, z-score -0.65) is in agreement with the men-
tioned inactivation process of TGF-β1 after PRGF treatment in comparison to AS.
Discussion
In the present study the protein expression patterns induced by PRGF and AS eye drops treat-
ment over human myofibroblasts have been characterized. Human keratocytes were treated
with TGF-β1 in order to induce their differentiation towards myofibroblasts. Then, these cells
were treated with either AS or PRGF and protein expression patterns were analyzed by means
of mass-spectrometry.
According with previous observations, our results provide molecular evidences consistent
with a myofibroblastic differentiated phenotype in AS treated-cells, whereas PRGF-treated
cells show attenuation on this phenotype. Previous results from our group demonstrated that
PRGF inhibits and reverts TGF-β1-induced myodifferentiation by diminishing the levels of
the myofibroblastic phenotype characteristic proteins α-actin (α-SMA), vimentin and desmin
in conjunctival fibroblasts and keratocytes regarding to autologous serum [32–34]. Consistent
with this idea, many down-regulated proteins upon PRGF treatment, such as vimentin, vincu-
lin, cortactin and actin related proteins -2 and -3 (ARP2 and ARP3 respectively), are cytoskele-
tal proteins present in the myofibroblastic phenotype. Cortactin and α-actinin are involved
with actin-assembly and remodeling [35] and ARP2 and ARP3 are involved in the organiza-
tion of the actin cytoskeleton and serve as nucleation sites for new branched actin filaments
[36]. Vinculin is a cytoskeletal protein associated with cell-cell and cell-matrix junctions and
vimentin is a major constituent of the intermediate filament family of proteins that acts during
corneal remodeling [34]. Another interesting protein, profilin 1, is an actin-binding protein
that at low concentrations enhances polymerization of actin; in this case, this protein is down
regulated in AS treated cells, suggesting that AS could favor an elevation in actin levels.
The functional analyses carried out also point in this direction. Proteins that are downregu-
lated upon PRGF treatment or that are more abundant in AS-treated cells were clustered into
three main canonical pathway groups in the IPA analysis: A) actin cytoskeleton signaling (8
canonical pathways), B) integrins and their signal transduction (6 canonical pathways), and C)
protein synthesis, cell proliferation and motility (3 canonical pathways). This suggests a close
relationship between AS-treated cells and cytoskeletal functions (Fig 4A and 4B). On the other
hand, proteins upregulated upon PRGF-treatment or that are less abundant in AS-treated cells
reveal a greater association with processes such as protein synthesis, proliferation and cellular
motility (Fig 4C), mainly related to EIF2 signaling (eukaryotic translation initiation factor 2
alpha), EIF4 regulation (eukaryotic translation initiation factor 4) and mTOR signaling (mam-
malian Target of Rapamycin). Therefore, myofibroblastic phenotype protein profiling is
reduced in PRGF-treated cells. Several studies have demonstrated that an alteration in EIF2
pathway is related to the development of neurodegenerative, metabolic and cancer diseases
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[37, 38], while EIF4 is a protein complex involved in mRNA translation implicated in cell pro-
liferation [39]. In addition, mTOR is involved in the control of mRNA transcription, ribosome
formation, cell cytoskeleton organization, cell membrane transport, regulation of cell growth,
Fig 4. Upstream regulators analysis. IPA displays the likely molecular effectors of the protein deregulation observed.
TGF-β1 (A), SMAD3 (B) and SMAD4 (C)-related proteins are displayed.
https://doi.org/10.1371/journal.pone.0205073.g004
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proliferation and death [40–42]. Our results provide a link between PRGF-Endoret function
and protein synthesis, cell proliferation and motility, since these results are more significantly
related to this condition.
Inhibition of TGF-β1 activity might be the mechanism for the phenotype reversion upon
PRGF treatment. In vitro studies from our group showed that PRGF-Endoret inhibits and
reverts TGF-β1 induced myodiferentiation in gingival fibroblasts as well as in keratocytes and
conjunctival fibroblasts [32, 43]. There is also evidence that PRGF-Endoret treatment reduces
the number of myofibroblasts in a corneal wound healing animal model [20]. TGF-β1 is
involved in hereditary corneal dystrophies such as type II granular corneal dystrophy (GCDII)
[44], and it is related to glaucoma and inflammatory processes [45]. Furthermore, there is as
well a correlation between TGF-β1 tear levels and corneal haze formation in corneal refractive
surgery [46]. Therefore, the modulation of TGF-β1 expression through the use of PRGF eye
drops arises as a plausible strategy to treat several ocular surface pathologies.
The expression patterns analyzed in this work are consistent with this idea. PRGF or AS-
treated cells revealed a solid relationship with TGF-β1 signaling, which is necessary for the
stromal keratocytes due to its implication in the conversion of fibroblasts to myofibroblasts,
but this association is much more consistent in AS-treated cells, suggesting that TGF-β1 might
be less active in PRGF-treated cells. Our results come along with previous scientific evidence
that supports that PRGF participates in myofibroblastic reversion to fibroblasts, achieving cor-
neal transparency in corneal lesions [21].
Although this preliminary study has certain limitations due to the low number of donors, the
proteomic analysis performed could help to understand the molecular events underlying AS and
PRGF-driven tissue regeneration processes, providing novel data that agrees with the modulation
of TGF-β1 activity and the reversion of the myofibroblastic phenotype by PRGF described before.
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